Company Allakos Inc.

Equities

ALLK

US01671P1003

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:16:29 2024-12-03 pm EST			5-day change	1st Jan Change
1.095 ^USD	+3.30%		+23.01%	-59.71%

Nov. 06	Allakos Inc. Announces Upcoming Report for Phase 1 Trial of AK006 in Patients	CI
Nov. 06	Allakos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

Business description: Allakos Inc.

Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Companyâs most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.

Number of employees: 131

Sales by Activity: Allakos Inc.

Fiscal Period: December	2019	2020	2021	2022	2023

See all business segments

Geographical breakdown of sales: Allakos Inc.

Fiscal Period: December	2019	2020	2021	2022	2023

See all geographic segments

Managers: Allakos Inc.

Director	Title	Age	Since
Robert Alexander CEO	Chief Executive Officer	54	2017-03-31
Harlan Radford DFI	Director of Finance/CFO	54	2021-04-18
Adam Tomasi DFI	Director of Finance/CFO	54	2021-01-31
Chin Lee CTO	Chief Tech/Sci/R&D Officer	54	-
Mary Cromwell CTO	Chief Tech/Sci/R&D Officer	-	-

See ALLAKOS INC. governance

Members of the board: Allakos Inc.

Manager	Title	Age	Since
Steven James BRD	Director/Board Member	66	2016-03-31
Robert Alexander BRD	Director/Board Member	54	2017-03-31
Daniel Janney CHM	Chairman	58	2017-05-31
Paul Walker BRD	Director/Board Member	49	2017-10-31
Robert Andreatta BRD	Director/Board Member	62	2018-05-31
Amy Ladd BRD	Director/Board Member	66	2022-07-20
Dolca Thomas BRD	Director/Board Member	53	2023-07-30
Neil Graham BRD	Director/Board Member	65	2023-08-29

Composition of the Board of Directors

Shareholders: Allakos Inc.

Name	Equities	%	Valuation
BVF, Inc. 18.63 %	16,552,417	18.63 %	21 M $
NEA Management Co. LLC 6.919 %	6,147,260	6.919 %	8 M $
Fidelity Management & Research Co. LLC 6.044 %	5,370,247	6.044 %	7 M $
Deep Track Capital LP 5.627 %	5,000,000	5.627 %	6 M $
Vanguard Global Advisers LLC 3.955 %	3,514,345	3.955 %	4 M $

List of ALLAKOS INC. shareholders

Company details: Allakos Inc.

Allakos, Inc.

825 Industrial Road Suite 500

94070, San Carlos

+650 597 5002

http://www.allakos.com

Bio Therapeutic Drugs

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ALLAKOS INC.	+3.30%	+23.01%	-58.02%	-98.51%	94.7M
VERTEX PHARMACEUTICALS INCORPORATED	-1.61%	-1.58%	+31.11%	+125.56%	120B
REGENERON PHARMACEUTICALS, INC.	-1.65%	-0.05%	-8.58%	+18.50%	82.02B
ARGENX SE	-0.27%	+2.01%	+39.62%	+131.12%	37.36B
BIONTECH SE	-0.66%	-1.17%	+17.26%	-65.95%	28.1B
BEIGENE, LTD.	+0.54%	+7.65%	+14.16%	-34.17%	21.86B
WUXI APPTEC CO., LTD.	+2.15%	+6.56%	-36.96%	-63.05%	20.05B
GENMAB A/S	-1.29%	+5.08%	-30.26%	-37.67%	13.86B
SUMMIT THERAPEUTICS INC.	-4.30%	-6.31%	+699.49%	+259.77%	13.64B
INSMED INCORPORATED	+0.28%	-3.91%	+169.63%	+180.88%	12.96B
Average	-0.31%	+3.40%	+83.74%	+41.65%	34.99B
Weighted average by Cap.	-1.05%	+1.25%	+45.36%	+65.64%